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73% (range: 43 -100) for the detection of duodenal ulcer; 74% (range: 43 -92) for gastric ulcer; 89% (range: 73 -100) for gastric cancer; 82% (range: 75.0 -91.9) for oesophagitis; and 91% (range: 41 -100) for non-ulcer dyspepsia (NUD).
Younger patients were separated from older adult patients on the basis of a cut-off age of 45.
The authors also reported the baseline parameters for the prevalence of H. pylori, healing rates, recurrence rates, treatment failure and cure rates.
Methods used to derive estimates of effectiveness
An expert panel of gastroenterologists made assumptions about effectiveness for which no data were available.
Estimates of effectiveness and key assumptions
The expert panel assumed that symptomatic failure rate in NUD patients who where H. pylori negative before and after treatment at 1 year was 70% (range: 50 -100). They also assumed that the median length of time to treatment failure in NUD patients was 4 months (range: 2 -6). Finally, the sensitivity and specificity of the 13C and 14C urea breath tests were assumed to be equivalent.
Measure of benefits used in the economic analysis
The proportion of patients remaining symptom-free over a 12-month time period after initial therapy was used as the measure of benefits (number of patients cured per 100 patients).
Direct costs
The direct costs to the health service were included in the analysis. These included pharmacological treatments, physician visits, diagnostic tests and complications. The cost of endoscopy was calculated using a micro-costing, timemotion study carried out at the Montreal General Hospital. Other unit costs were derived from the Quebec Drug Plan, Conseil Consultatif de Pharmacologie, Capsules Pharmacotherapeutiques, Quebec Ministry of Health and Social Services and Quebec physician fee schedule. Complications and costs relating to possible development of oesophagitis after H. pylori eradication were not considered. The costs appear to have been expressed in 1998 prices. The costs were not discounted as the time horizon chosen was 12 months.
Statistical analysis of costs
The costs were treated as point estimates (i.e. the data were deterministic). The costs for each arm of the decision tree were calculated using the expected value approach.
Both one-way and multi-way sensitivity analyses were performed. Five key variables were varied using ranges obtained from the review of the literature. These variables were symptomatic recurrence rates, prevalence of duodenal ulcer in young patients, prevalence of H. pylori in duodenal ulcer patients, specificity of UBT and the symptomatic relapse rate in H. pylori-negative NUD patients. A threshold analysis was performed on three key parameters, that is, gastric cancer rate, cost attributable to UBT and laboratory serology costs.
Estimated benefits used in the economic analysis
For patients aged between 18 and 45 years, the numbers of patients cured with each strategy were as follows: Detailed results for the numbers of patients cured in the over 45-year age group for the different alternatives were not presented. Compared with empirical eradication treatment, UBT cures 0.46 additional patients per 100. Evidence suggested that 2% of older patients had gastric cancer. All cases of gastric cancer were detected using a policy of early endoscopy.
Cost results
For patients aged between 18 and 45 years, the costs of the strategies were as follows: The incremental costs were Can$14,644 for serology compared with empirical antisecretory treatment, Can$2,693 for empirical eradication compared with serology, and Can$3,650 for the UBT compared with empirical eradication.
Detailed costs for the different alternatives in the over 45-year age group were not presented.
Synthesis of costs and benefits
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The costs and benefits were synthesised using the incremental cost-effectiveness ratio (ICER). Dominated and extended dominated alternatives were removed before applying the incremental analysis.
For patients aged between 18 and 45 years, endoscopy and sequential testing were dominated by laboratory serology. A combination of empirical antisecretory and laboratory serology approaches was more cost-effective than the barium strategy. The remaining four strategies were cost-effective in this patient group. The ICER of serology compared with empirical antisecretory treatment was Can$2,970 per additional patient cured. The ICER of empirical eradication therapy compared with serology was Can$6,412 per additional patient cured. Finally, the ICER of UBT compared with empirical eradication therapy was Can$10,429 per additional patient cured.
For patients aged over 45 years, empirical antisecretory treatment, barium examination, empirical eradication therapy and UBT were the cost-effective interventions. The ICER of UBT compared with empirical eradication therapy was Can$10,835 for each additional patient cured. The ICER of UBT compared with barium testing was Can$4,114 per additional patient cured.
Endoscopy became cost-effective when the difference in symptomatic recurrence rates dropped to less than 6.3%. When this difference dropped to 3% or lower, endoscopy and empirical antisecretory strategies were the only costeffective alternatives in younger patients. The same result was achieved in the older group of patients, with a cut-off of 5.4%. When the cost of a UBT decreased to Can$44.28 and Can$36.60, laboratory serology and empirical eradication, respectively, were no longer cost-effectiveness strategies.
